奇正藏药藏药获澳门注册批准 股价近期震荡机构看好政策受益

Group 1 - The core viewpoint of the articles highlights that Qizheng Tibetan Medicine has received registration approval for its classic Tibetan medicine, which marks a significant step in its internationalization strategy as it becomes the first Tibetan medicine approved in Macau [1] - Additionally, the company has obtained approval for another product in the respiratory field, reinforcing its positioning in this sector [1] Group 2 - In the past week, Qizheng Tibetan Medicine's stock price fluctuated within a range of 2.47%, with a volatility of 7.09%. The latest closing price was 24.43 yuan, reflecting a daily decrease of 1.61%. The technical analysis indicates that the stock price is near the middle band of the Bollinger Bands, suggesting some pressure and support [2] - Zhongyou Securities has released a report indicating that the recently published "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry" supports the development of leading enterprises in the traditional Chinese medicine sector. Qizheng Tibetan Medicine is identified as a beneficiary company, with predictions of continued net profit growth over the next two years [3]